Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Despite recent market volatility, buying shares of top companies that can at least match average returns through 2035 -- or ...

Gulf South Angels, a New Orleans-based investment network, is investing in non-opioid pain drug startup South Rampart Pharma, ...

In this first of a three-part video interview series, Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, shared his input on Managed Healthcare Executive’s annual Pharmacy ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine), an oral NaV1.8 inhibitor, as a treatment for acute pain, representing ...

The FDA has approved suzetrigine, a groundbreaking painkiller ... or overdose. Known as Journavx, this drug is the first in over two decades to introduce a new pain relief mechanism.

Management pointed to the initial launch of ALYFTREK, a fifth CF therapy, and the rollout of JOURNAVX, a non-opioid pain medication, as key contributors to revenue growth, while also noting ...

Acute pain management in the older adult is both challenging and rewarding. This review addresses the difficulty with assessment of pain in the older adult, variations in the pain experience of ...

The FDA approved Vertex Pharmaceuticals’ Journavx, the first non-opioid painkiller in more than 20 years. The FDA also greenlighted Soleno Therapeutics’ Vykat XR, the first-ever treatment for ...